Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "RAMOSE Trial - Osimertinib+/-Ramucirumab in TKI-Naïve EGFRm mNSCLC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Xiuning Le
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Xiuning Le
Login to view comments.
Click here to Login
Lung